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Background: Lymph node metastasis (LNM) is most common in esophageal squamous cell carcinoma (SCC). The
bi-directional spread is a key feature of LNM in patients with thoracic esophageal SCC (TE-SCC). The purpose of this
study was to analyze the prognostic factors of survival in patients with TE-SCC with cervical lymph node metastasis
(CLM) and validate the staging system of the current American Joint Committee on Cancer (AJCC) in a cohort of
Chinese patients.
Methods: Of 1715 patients with TE-SCC who underwent radical esophagectomy plus three-field lymph node dissection
at a single hospital between January 1993 and March 2007, 547 patients who had pathologically confirmed CLM
(296 had surgery only and 251 had surgery + postoperative radiotherapy) were included in this study. The locations
of the lymph nodes (LNs) were classified based on the guidelines of the Japanese Society for Esophageal Diseases.
Results: The rate of CLM was 31.9% for all patients and was 44.2%, 31.5%, and 14.4% for patients with upper, middle,
and lower TE-SCC, respectively (P < 0.0001). The rates of metastasis to 101 (paraesophageal lymph nodes), 104
(supraclavicular lymph nodes), 102 (deep cervical lymph nodes) and 103 (retropharyngeal lymph nodes) areas were
89.0%, 25.6%, 3.7% and 0.5%, respectively. The 5-year overall survival (OS) rate with CLM was 27.7% (median survival,
27.5 months). The 5-year OS rates were 21.3% versus 34.2% (median survival, 21.9 months versus 35.4 months) for after
surgery only versus surgery + postoperative radiotherapy, respectively (P < 0.0001 for both). Multivariate analysis showed
that the independent prognostic factors for survival were sex, pT stage, pN stage, number of fields with positive LNs,
and treatment modality. In surgery only group, the 5-year OS rates were 24.1%, 16.2% and 11.7%, respectively, when
there was metastasis to 101 LN alone, 104 LN alone or both 101 LN and 104 LN. The 5-year OS rates were 17.7%, 22.5%
and 31.7%, for patients with upper, middle and lower TE-SCC , respectively (P = 0.112). The 5-year OS rates were 43.0%,
25.5%, 10.2% in patients with 1 field (cervical LNs), 2 fields (cervical +mediastinal, and/or cervical + abdominal LNs), and
3 fields (cervical +mediastinal + abdominal LNs) positive LNs, respectively (P < 0.0001). The number of fields of positive
LNs did not impact the OS according to different pN stage (all P > 0.05).
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Conclusion: Patients with TE-SCC with CLM have better prognosis, which supports the current AJCC staging system for
esophageal SCC.
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Lymph node metastasis (LNM) is most common in
esophageal squamous cell carcinoma. The bi-directional
or skip node spread is a key feature of LNM in patients
with thoracic esophageal squamous cell carcinoma (TE-
SCC), with a metastasis rate of 23.4-49.5% in the cervical
node [1-4].
In the past two decades, advances in esophageal cancer
surgery have been remarkable. Radical esophagectomy
with extensive lymphadenectomy in the mediastinum,
abdomen, and neck (so-called three-field lymphadenec-
tomy, 3FL) has been the mainstay treatment for TE-
SCC. The surgical approach can sufficiently expose the
surgical field and completely dissect related lymph nodes
with metastasis [1-5].
According to the Guidelines for Clinical and Patho-
logic Studies on Carcinoma of the Esophagus issued by
the Japanese Society for Esophageal Diseases, the cer-
vical lymph nodes (LNs) were classified into 101 (parae-
sophageal nodes), 102 (deep cervical nodes), 103
(retropharyngeal LNs), and 104 (supraclavicular LNs)
areas. Each area is divided into left and right parts [6].
In the seventh edition of the American Joint Committee
on Cancer tumor node metastasis (AJCC TNM) staging
system for esophageal squamous cell carcinoma issued
in 2009, LNs from the neck to the abdomen are defined
as regional LNs. In the sixth edition AJCC TNM staging
system, the subdivision of “M” classification into M1A
and M1B according to the presence of nonregional LN
involvement is not longer used [5]. In addition, whether
metastasis to the cervical LNs, especially supraclavicular
LNs (104), should be classified as local or distant metas-
tasis has not be proposed. In the present retrospective
study, the prognostic factors were analyzed in 547 pa-
tients with TE-SCC with cervical LNM after receiving
extended esophagectomy with 3FL.Methods
Patient population
From January 1993 to March 2007, 1715 consecutive pa-
tients with biopsy-proven TE-SCC were treated with
3FL at the Fujian Province Cancer Hospital, Fujian Med-
ical University, Fuzhou, Fujian, China. Medical records
of these patients were retrieved. Patients meeting the
following criteria were selected for this study: (1) patho-
logically confirmed as squamous cell carcinoma of the
esophagus and underwent extended esophagectomy plus3FL, (2) the number of dissected LNs was ≥15, (3) pre-
surgical enhanced computed tomography scan did not
reveal LN with a diameter >1 cm in the cervical area
(including supraclavicular area), (4) did not undergo
chemotherapy and radiotherapy before esophagectomy
and did not undergo chemotherapy after esophagec-
tomy, and (5) did not have distant metastasis. According
to the seventh edition of the AJCC TNM staging system
released in 2009, N is subclassified based on the number
of positive regional LNs (N1, 1-2 positive LNs; N2, 3-6
positive LNs; and N3, ≥7 positive LNs) [5]. This study
was performed in accordance with the Declaration of
Helsinki and was approved by the ethics committee of
Fujian Provincial Cancer Hospital. All patients provided
written informed consent form for storage of their infor-
mation in the hospital database and for using this infor-
mation in this study. Of the 1715 patients, 547 patients
were with cervical LNM, 296 patients underwent esoph-
agectomy only, and 251 patients underwent radiotherapy
after esophagectomy. The field of LNM was in accord-
ance with the cervical, mediastinal, and abdominal LNs.
Surgical procedures
The resection of the thoracic esophagus was performed
through a cervical incision, a right thoracotomy, and a
laparotomy. Details of the procedure were described
elsewhere [1]. According to the guidelines for clinical
and pathologic studies on carcinoma of the esophagus
issued by the Japanese Society for Esophageal Diseases,
the cervical LNs were classified into 101 (paraesophageal
nodes), 102 (deep cervical nodes), 103 (retropharyngeal
lymph nodes) and 104 (supraclavicular nodes) areas.
Each area is divided into left and right parts [6].
Radiotherapy
Patients underwent radiotherapy 3-4 weeks after esopha-
gectomy. T-shaped fields were used. The T-shaped field
included bilateral supraclavicular fossi, mediastinum, left
gastric nodes, and the tumor bed. The medium total ra-
diation dose consisted of 50 Gy for the tumor bed ad-
ministered in 2 Gy of daily dose fractions, 5 fractions a
week, over a period of 5 weeks [7].
Follow-up
Patients were instructed to undergo follow-up evalua-
tions every 3 months for the first year, every 6 months
for the next 2 years, and annually thereafter. As of May
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cording to the schedule. Survival status of patients who
did not come at the scheduled follow-up times was up-
dated through telephone calls or letters every 6 months.
Survival status of patients who could not be reached in
this manner was obtained through the Fujian Public
Safety Bureau’s registration center system. In total, 1336,
799, and 447 patients were followed up for 1, 3, and
5 years, respectively.Statistical analysis
Statistical analysis of group differences was performed
using the Chi-square test for categorical variable data.
Survival plots of patients were constructed using the
Kaplan-Meier method and were compared using the
log-rank test. A Cox regression proportional hazard
multivariate analysis was performed to identify statisti-
cally significant factors associated with overall survival
(OS). P < 0.05 was considered to be statistically signifi-
cant. All statistical analyses were performed using the
software package SPSS 15.0.Results
Rate and pattern of LNM
In total, 547 of the 1715 patients met the inclusion cri-
teria. The mean number of dissected LNs was 25.8
(range, 15-73). The frequency of any LNM was 31.9%.
Specifically, the rates of cervical LNM for upper, middle,
and lower TE-SCC were 44.2%, 31.5%, and 14.4%, re-
spectively (P < 0.0001) (Table 1). The rates of LNM to
101, 104, 102, and 103 regions were 28.4%, 8.2%, 1.2%,
and 0.2%, respectively. The rates of LNM from upper,
middle, and lower TE-SCC to 101 and 104 were signifi-
cantly different (P < 0.05) (Table 1). For patients with
cervical metastasis, the rates of LNM to 101, 104, 102,
and 103 regions were 89.0%, 25.6%, 3.7%, and 0.5%,





Number of patients (%) 1715 (100) 274 (16.0)
Mean number of dissections
Nodes per patient (range) 25.8 (15-73) 26.8 (15-68)
Number of positive CLM (%) 547 (31.9) 121 (44.2)
Paraesophageal (101), n (%) 487 (28.4) 108 (39.4)
Deep cervical (102), n (%) 20 (1.2) 7 (2.6)
Retropharyngeal (103), n (%) 3 (0.2) 2 (0.7)
Supraclavicular (104), n (%) 140 (8.2) 31 (11.3)
Abbreviations: CLM cervical lymph node metastasis, LNM lymph node metastasis, TERelationship between cervical lymph node metastasis and
survival
The 3-year and 5-year survival rates for patients (n =
547) with LNM were 41.5% and 27.7%, respectively. The
median survival was 27.5 months. The 5-year survival
rates and the median survival times were 21.3% versus
34.2%, and 21.9 months versus 35.4 months after surgery
only (n = 296) versus surgery plus postoperative radio-
therapy (n = 251), respectively [P < 0.0001 for both, haz-
ard ratio (HR) (95% CI) 0.641 (0.521-0.788)] (Figure 1).
In surgery only group, the 5-year OS rates for patients’
metastasis to 101 LN alone, 104 LN alone or both 101
LN and 104 LN were 24.1%, 16.2%, and 11.7%, respect-
ively. The median survival times were 23.3 months,
20.0 months, and 17.7 months, respectively [P = 0.117,
HR (95% CI) 1.129 (0.996-1.280)] (Figure 2). The 5-year
OS for patients with upper, middle, and lower TE-SCC
were 17.7%, 22.5%, and 31.7%, respectively. The corre-
sponding median survival times were 17.3 months,
22.6 months, and 37.2 months, respectively [P = 0.112,
HR (95% CI) 0.734 (0.549-0.980)] (Figure 3).
Analysis of prognostic factors of survival
Univariate analysis showed that sex, tumor length by x-
ray, pT stage, pN stage, the number of fields with posi-
tive LNs, and treatment modality were predictors for
survival. Age, tumor location, and histopathological type
were not statistically significant predictors of survival
(P > 0.05) (Table 2).
Multiple Cox regression indicated that sex, pT stage,
pN stage, the number of fields with positive LNs, and
treatment modality were independent predictors for sur-
vival (Table 3).
Survival of different fields of positive lymph nodes
according to the pN stage
The 5-year OS rates were 43.0%, 25.5%, 10.2% in pa-
tients with 1 field (cervical LNs), 2 fields (cervical + me-
diastinal, and/or cervical + abdominal LNs), and 3 fieldsphageal tumor
Middle Lower χ2 Value P-value
1281 (74.7) 160 (9.3)
25.7 (15-71) 24.7 (15-73)
403 (31.5) 23 (14.4) 41.698 <0.0001
358 (27.9) 21 (13.1) 34.843 <0.0001
12 (0.9) 1 (0.6) 5.575 0.062
1 (0.1) 0 (0.0) 5.802 0.055
104 (8.1) 5 (3.1) 9.049 0.011
-SCC thoracic esophageal squamous cell carcinoma.
Figure 1 Overall survival of patients who underwent surgery only (S, blue line) and who underwent surgery followed by radiation (S + R,
green line) for thoracic esophageal squamous cell carcinoma.
Figure 2 Overall survival of patients presenting with positive nodes in the 104 region (green line), the 101 region (blue line), and in both
(red line) regions.
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Figure 3 Overall survival of patients presenting with positive nodes in the lower region (i.e., middle and lower mediastinal and upper
abdominal beds) (red line), the upper region (i.e., cervical and upper mediastinal beds) (blue line), and in the middle region (green line).
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respectively [P < 0.0001, HR (95% CI) 1.643 (1.437-
1.878)] (Figure 4A). Subgroup analysis showed that the
number of fields of positive LNs did not impact the OS
according to different pN stage (all P > 0.05) (Table 4
and Figure 4B-D). The OS between cervical + medias-
tinal positive LNs and cervical + abdominal positive LNs
were not significantly different (Table 4 and Figure 5).
Pattern of disease progression
Postoperative radiotherapy reduced the recurrence rate
of cervical and mediastinal LN compared with surgery
alone (P < 0.05). The pattern of disease progression in
patients with and without postoperative radiotherapy is
shown in Table 5.
Toxicity of postoperative radiotherapy
Early toxicities related to postoperative radiotherapy
were gastrointestinal reactions (swallowing pain and
loss of appetite) accounting for 28.3% (71 patients),
bronchitis (cough) accounting for 21.1% (53 patients),
and leukopenia accounting for 34.3% (86 patients,
including 80 patients with grade 1-2 and 6 patients with
grade 3).
Late toxicities were nonmalignant pleural effusion
pericardial accounting for 2.4% (6 patients), radiation-
induced pulmonary fibrosis accounting for 2.0% (5patients), thoracic ulcer bleeding accounting for 1.2%
(3 patients), anastomotic stricture accounting for 1.6%
(4 patients), and anastomotic fistula accounting for 0.4%
(1 patient).
Discussion
In the present study, pertinent results include that
cervical LNM was the highest in patients with upper
TE-SCC, followed by patients with middle and lower
TE-SCC. Metastasis to paraesophageal nodes was most
common. Metastasis to deep cervical nodes was less
common. Metastasis to either retropharyngeal LNs or
supraclavicular LNs was rare. The 5-year survival rates
of patients undergoing surgery only were similar irre-
spective of whether there was metastasis to 101 LN
alone, 104 LN alone, or both 101 LN and 104 LN. Multi-
variate factor analysis showed that the independent
prognostic factors for survival were sex, pT stage, pN
stage, the number of fields with positive LNs, and treat-
ment modality. Cervical lymph node metastasis (CLM)
was independent of tumor location.
There is controversy with regard to the prognostic sig-
nificance and staging classification of cervical LNM in
patients with TE-SCC. Most studies suggest that patients
with cervical LNM have a better prognosis than those
with hematogenous metastasis and thus cervical LNM
should be included in “N” instead of “M” staging. Lerut
Table 2 Univariate analysis of prognostic factors of survival in patients with TE-SCC with CLM
5-year Median survival
Variable All (%) Survival rate (%) (Months) χ2 value P-value
Patients 547 (100) 27.7
Sex 8.323 0.004
Male 406 (74.2) 24.6 24.8
Female 141 (25.8) 37.0 39.5
Age (years) 0.225 0.635
<60 335 (61.2) 27.8 25.9
≥60 212 (38.8) 27.1 31.5
Thoracic tumor location 0.456 0.796
Upper 121 (22.1) 31.7 29.2
Middle 403 (73.7) 26.6 26.8
Lower 23 (4.2) 23.3 25.5
Differentiation 1.623 0.444
Low 118 (21.6) 23.4 24.1
Intermediate 349 (63.8) 29.1 27.8
High 80 (14.6) 28.6 28.3
Tumor length (cm) 7.638 0.006
≤5 283 (51.7) 31.7 32.0
>5 264 (48.3) 23.4 23.6
pT stage 20.517 <0.0001
pT1 16 (2.9) 86.7 53.6
pT2 84 (15.4) 41.6 43.4
pT3 386 (70.6) 23.1 26.4
pT4 61 (11.2) 23.2 22.5
Number of nodal metastases 63.872 <0.0001
1-2 226 (41.3) 43.3 49.7
3-6 221 (40.4) 20.3 23.5
≥7 100 (18.3) 9.9 16.7
Number of fields with positive lymph nodesa 55.313 <0.0001
1 field 191 (34.9) 43.0 43.3
2 fields 214 (39.1) 25.5 29.2
3 fields 142 (26.0) 10.2 19.3
Treatment program 18.145 <0.0001
Surgery only 296 (54.1) 21.3 21.9
Surgery + radiation 251 (45.9) 34.2 35.4
Abbreviations: CLM cervical lymph node metastasis, TE-SCC thoracic esophageal squamous cell carcinoma.
a1 field (cervical lymph nodes), 2 fields (cervical + mediastinal, and/or cervical + abdominal lymph nodes), 3 fields (cervical +mediastinal + abdominal lymph nodes)
with positive lymph nodes.
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tive LNs was 27.2% after 3FL in patients with middle
TE-SCC [8]. Fang et al. reported that 5-year OS for pa-
tients with positive cervical nodes was 20.0% after 3FL
with TE-SCC [9]. Tachimori et al. reported that 3-year
OS for patients with positive cervical nodes was 43.8%
after 3FL with TE-SCC [10]. Hsu et al. enrolled 488 pa-
tients who underwent primary curative resection withoutneoadjuvant therapy for esophageal cancer between
1995 and 2006. They found the 3-year OS rate was
35.4%. The 3-year OS rate was equivalent among pa-
tients in N1 (23.3%), M1a (22.0%), and nonregional
LNM-related M1b (18.5%). No survival difference was
noted (18.5%). However, differences in survival rate were
evident between patients with and without distant me-
tastasis (P < 0.001) [11]. Kato et al. reported that in
Table 3 Multivariate analysis of prognostic factors of survival in patients with TE-SCC with CLM
Variable Regression coefficient B SE Wald value HR (95% CI) P-value
Sex (male vs. female) -0.294 0.127 5.342 0.745 (0.581-0.956) 0.021
Tumor length (≤5 cm vs. >5 cm) 0.202 0.106 3.651 1.224 (0.995-1.505) 0.056
pT category (T1, 2, 3, 4) 0.283 0.096 8.687 1.327 (1.100-1.602) 0.003
Number of nodal metastases (1-2, 3-6, ≥7) 0.332 0.102 10.533 1.393 (1.140-1.702) 0.001
Fields of LNM (1 field, 2 fields, 3 fields) 0.203 0.100 4.109 1.225 (1.007-1.490) 0.043
Treatment program (surgery only vs. surgery + radiation) -0.414 0.107 15.025 0.661 (0.536-0.815) <0.0001
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with cervical LNM was significantly better than that of
patients with hematogenous metastasis (P = 0.002). In
patients without hematogenous metastases, the survival
curve for the patients with histologic cervical LNM did
not significantly differ from that of patients with medias-
tinal or abdominal LNM [12]. Rice et al. also found that the
survivals were similar between patients in M0 classification
and M1 classification (P < 0.0001). However, the survivals
were significantly different between patients in M1a sub-
classification and M1b subclassification (P = 0.9) [13].
The results from the current study are similar to
those reported by other researchers and support the
current AJCC staging system which considers cervical
LN to be regional LN [8-12]. The patients with
cervical LN metastasis are classified as one group ac-
cording to the AJCC staging system, and there is no
explicit deliberation on whether the LNs adjacent to
the cervical esophagus and supraclavicular LNs should
be included. However, the cervical LN metastasis is
classified elaborately into four groups including
cervical esophageal LNs, cervical posterior deep LNs,
retropharyngeal LNs, and supraclavicular LNs by the
Japanese Society for Esophageal Diseases, though there
was no published report on the prognosis related to
this classification on cervical LNM. In the present
study, the patients who underwent surgery only were
classified into three groups, group of cervical esopha-
geal LN metastasis, group of supraclavicular LN
metastasis, and group of both cervical esophageal andFigure 4 The survival of different fields of positive lymph nodes acco
(B), pN2 stage (C), and pN3 stage (D).supraclavicular LN metastasis. The stratified analysis
on these three groups indicated that there was no sig-
nificant difference in terms of 5-year survival rate,
with the rate of 24.1%, 16.2%, and 11.7%, respectively
(P = 0.117). These findings were in accordance with
the concept defined by the AJCC staging system (sev-
enth edition) that all cervical LN metastasis shall be
regarded as one common regional LN metastasis.
In the present study, the 5-year survival rates in the
postoperational radiotherapy group and surgery only
group were 34.2% and 21.3%, respectively (P < 0.0001).
The improvement in survival rate by postoperational
radiotherapy might be due to blood vessels, lymphatic
vessels, and surrounding organs, exposure of the lower
cervical area is challenging during esophagectomy and
complete removal of LNs is sometimes impossible,
which will cause recurrence after surgery. Postoperative
radiotherapy will reduce metastasis and increase sur-
vival [14].
It was widely believed that the number of fields of
cervical LN metastasis was a vital factor for prognosis
of thoracic esophageal carcinoma [13,15], which was
consistent with the results of the present study that
the number of fields of cervical LN metastasis was an
independent factor of prognosis. The further stratified
analysis indicated that the number of fields of cervical
LN metastasis and survival rate were not significantly
different among the patients with different numbers of
positive LNs (P > 0.05), and the possible underlying
reason might be that the number of positive LNs isrding to the different pN stages as entire group (A), pN1 stage
Table 4 Survival of different fields of positive lymph nodes according to the pN stage
5-year Median survival
Variable All (%) Survival rate (%) Time (months) χ2 value P-value
pN1 2.136 0.144
1 field 160 (29.3) 45.6 51.8
2 fields 66 (12.1) 36.8 42.3
pN2 1.940 0.379
1 field 30 (5.5) 32.6 24.2
2 fields 126 (23.0) 20.3 24.9
3 fields 65 (11.9) 15.5 21.9
pN3 2.311 0.315
1 field 1 (0.2) 0.0 31.5
2 fields 22 (4.0) 25.0 16.7
3 fields 77 (14.1) 5.1 14.7
Fields of LNM 0.154 0.695
C + M 163 (76.2) 23.7 25.9
C + A 51 (23.8) 30.1 34.0
Abbreviations: A, abdominal; C, cervical; LNM, lymph node metastasis; M, mediastinal.
a1 field (cervical lymph nodes), 2 fields (cervical + mediastinal, and/or cervical + abdominal lymph nodes), 3 fields (cervical +mediastinal + abdominal lymph nodes)
with positive lymph nodes.
Abbreviations: CI = confidence interval; CLM = cervical lymph node metastasis; HR = hazard ratio; LNM, lymph node metastasis; SE = standard error; TE-SCC = thor-
acic esophageal squamous cell carcinoma.
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plying that the number of positive LNs is the most
critical factor for prognosis instead of number of fields
of metastasis.Figure 5 The survival of patients with positive lymph node betweeConclusion
This study demonstrates that patients with TE-SCC with
cervical LNM have a better prognosis. Five-year survival in
patients with TE-SCC with metastasis to paraesophagealn cervical + mediastinal group and cervical + abdominal group.
Table 5 Pattern of disease progression
Variable Surgery




(n = 251) (%)
χ2 value P-value
Site of lymph node metastasis
Cervical
lymph nodes
42 (14.2) 13 (5.2) 12.192 <0.0001
Mediastinal
lymph nodes
23 (7.8) 9 (3.6) 4.318 0.038
Abdominal
lymph nodes
10 (3.4) 13 (5.2) 1.094 0.296
Tumor bed 6 (2.0) 2 (0.8) 1.426 0.2326
Distant
metastasis




126 (42.6) 93 (37.1) 1.721 0.190
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http://www.biomedcentral.com/1471-2482/14/110nodes was similar to those with metastasis to supraclavicu-
lar LNs and supports the staging system of the current
AJCC for esophageal squamous cell carcinoma that classi-
fies cervical LN as regional LN. These patients will benefit
from postoperative radiotherapy. Further perspective stud-
ies are needed to validate the conclusion.Abbreviations
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